The total number of records retrieved from this search are 18. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_898	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result2% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_899	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result20% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_900	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result50% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_901	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result20% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_902	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result40% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_903	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result80% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_904	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result60% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_905	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result80% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_906	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result90% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_907	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result20% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_908	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result30% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_909	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result50% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_910	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result50% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_911	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result60% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_912	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result100% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_913	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result60% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_914	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result80% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_915	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result100% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429